ICOA yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ICOA pulled ahead of the other in Year 1
Combined, ICOA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ICOA + ABBV for your $10,000?
ICOA, Inc. provides neutral-host wireless and wired broadband Internet services in the United States. It offers back office solutions for hotspot operators and wireless service providers. The company also provides network advisory services, as well as procures, configures, and installs network equipment; and equipment, administration, billing, business intelligence, and content management flexibility services. In addition, it engages in the design, installation, operation, maintenance, and management of neutral, common-use 802.11x standard WLAN Wi-Fi hot spot, and hot zone infrastructure facilities in airport, quick-service restaurants, universities, travel plazas, marinas, hospitality, and municipal/hot zone locations. ICOA, Inc. owns and operates approximately 1,500 broadband access installations in 45 states; the LinkSpot network in RV parks and campgrounds; and the iDockUSA network in marinas. The company was formerly known as Quintonix, Inc. and it changed its name to ICOA, Inc. in March 1989. ICOA, Inc. was founded in 1983 and is headquartered in Warwick, Rhode Island.
Full ICOA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.